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ERECTILE IMPLANTS IN FEMALE-TO-MALE TRANSSEXUALS: OUR
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Introduction & Objectives: Female-to-male transsexuals who desire sexual 
intercourse still need an erectile implant in their reconstructed phallus. Less is 
known about the complications of this surgery in female-to male transsexuals. We 
reviewed the complication rate of erectile implant surgery at our centre.
Material & Methods: 2QDWRWDORIPRUHWKDQIHPDOHWRPDOHWUDQVVH[XDOV
SDWLHQWVUHFHLYHGDQHUHFWLOH LPSODQWEHWZHHQ'HFHPEHUDQG2FWREHU
'LᚎHUHQWW\SHVRISURVWKHVHVZHUHLPSODQWHG'\QDᚐH[© in 9 patients, AMS 
CX©, AMS Ambicor© and Porges© in 68, 47 and 6 patients respectively. Mean 
follow-up was 22.2 months (range: 1-118 months). We reviewed the explantation 
rate and the cause of explantation in each group.
Results: 2IWKHSDWLHQWVSDWLHQWVVWLOOKDYHWKHLURULJLQDOLPSODQWLQ
place. Fifty-eight patients (44.6%) needed to undergo either removal of the prosthesis 
GXHWR LQIHFWLRQRUHURVLRQSDWLHQWVRUUHYLVLRQGXHWRG\VIXQFWLRQRU
OHDNSDWLHQWV,QWKH'\QDᚐH[©-group, 8 of 9 patients needed revision 
due to dysfunction (88.9%) but no removals due to infection, protrusion or leakage 
were reported. In the Porges©-group, only 1 of 6 patients (16.7%) needed revision 
due to dysfunction but no other complications were reported. In the AMS CX©-
JURXSRISDWLHQWV QHHGHGH[SODQWDWLRQGXH WR LQIHFWLRQHURVLRQ
dysfunction or leakage in respectively 8 (11.8%), 2 (2.9%), 11 (16.2%) and 12 
(17.6%) patients. In the AMS Ambicor©JURXSH[SODQWDWLRQVZHUHGRQH
because of infection, erosion, dysfunction and leakage for 4 patients each.
Conclusions: Despite a high explantation rate (44.6%) due to infection, erosion, 
dysfunction or leakage implantation of an erectile implant is the only valuable 
option for female-to-male transsexuals to obtain satisfactory intercourse. Patients 
must absolutely be informed about these possible complications but should not be 
discouraged.
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SIX-MONTH CONCOMITANT AND ADJUVANT HORMONAL
TREATMENT WITH EXTERNAL BEAM IRRADIATION IS INFERIOR
TO 3-YEARS HORMONAL TREATMENT FOR LOCALLY ADVANCED 
PROSTATE CANCER: RESULTS OF THE EORTC RANDOMISED
PHASE III TRIAL 22961
Bolla M.1, De Reijke Th.M.2, Van Tienhoven G.J., Van Den Bergh A.C.M.4, Oddens J.5,
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Introduction & Objectives: $IWHU(257&WULDO\HDUVRIHQGRFULQHWUHDWPHQWLVQRZVWDQGDUG
DGMXYDQW WUHDWPHQW WR ' H[WHUQDO EHDP LUUDGLDWLRQ (%57 IRU ORFDOO\ DGYDQFHG SURVWDWH FDQFHU
(PCa). In EORTC trial 22961 70 Gy EBRT and 6 months of combined androgen deprivation (SADT 
arm) was randomly compared to the same treatment followed by 2.5 further years of LH-RH agonist 
(62% triptoreline) monotherapy (LADT arm), aiming non inferior overall survival (OS) and possibly 
earlier recovery of testosterone on the SADT-arm
Material & Methods: Eligible patients had T1c-2b N1-2 or pN1-2, or T2c-4 N0-2 M0 PCa (UICC 1992) 
ZLWK36$QJPO1RQLQIHULRU26ZDVGHᚏQHGDVDPRUDOLW\KD]DUGUDWLR+5ืIRU6$'7
YV/$'71RQ LQIHULRULW\DWSRZHUDQGVLGHG˞  UHTXLUHGGHDWKV$IWHUDQ LQWHULP
analysis conducted in September 2006, the Independent Data Monitoring Committee recommended 
WKHGLVFORVXUHRIWKHVWXG\UHVXOWV)LQDOUHVXOWVDUHWKXVSUHVHQWHGDWVLGHG˞ RZLQJWRRQH
interim analysis. OS is compared with the LogRank test.
Results: SDWLHQWVZHUH UDQGRPL]HG 6$'7DQG/$'7$W  \HDUVPHGLDQ IROORZ
XSSDWLHQWVKDGGLHGYV7KHSDWLHQWFKDUDFWHULVWLFVZHUHZHOOEDODQFHGPHGLDQDJH
\HDUV:+236LQRIWKHSDWLHQWVKDG7ื7F1S13&D3URJUHVVLRQPRVWO\
biochemical and/or bone progression) occurred in 281 pts (196 on SADT vs. 85 on LADT) and was 
treated by secondary hormonal manipulation. The 5-year overall survival rate with SADT was 81.1% 
versus 85.1% with LADT (HR=1.47, 95.7% CI: 1.12-1.94), and failed to prove non-inferiority (the 
ORZHUERXQGRIWKH&,EHLQJ!&OLQLFDOSURJUHVVLRQIUHHVXUYLYDOZDVVLJQLᚏFDQWO\ZRUVHRQ6$'7
with 5-year event-free rate of 68.7% vs. 80.5% on LADT (HR=1.77, P<0.0001). Likewise, the 5-year 
biochemical progression-free survival rate was 56.8% on SADT vs. 77.7% on LADT (HR=2.20, 
37KHUHVXOWVZHUHVLPLODULQWKHVXEJURXSZLWK7ื7F1S13&D
Conclusions: 7KHVWXG\LQGLFDWHGWKDWVXUYLYDOZLWKPRQWKV$'7DIWHULUUDGLDWLRQZDVVLJQLᚏFDQWO\
VKRUWHUWKDQZLWKWR\HDUVDGMXYDQW$'7IRUSDWLHQWVZLWKORFDOO\DGYDQFHG3&D3URJUHVVLRQIUHH
survival was also shorter with SADT
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EXTERNAL-BEAM RADIATION THERAPY INCREASES THE
RATE OF SECONDARY MALIGNANCIES RELATIVE TO RADICAL
PROSTATECTOMY IN MEN WITH PROSTATE CANCER
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Introduction & Objectives: 6HYHUDO SUHYLRXV UHSRUWV DGGUHVVHG WKH HᚎHFW RI
external-beam radiation therapy (EBRT) on the rate of secondary malignancies 
LQSDWLHQWVZLWKORFDOL]HGSURVWDWHFDQFHU&RQᚐLFWLQJUHVXOWVZHUHUHSRUWHG:H
addressed the association between EBRT exposure and secondary malignancies 
rate in a large administrative database.
Material & Methods: 7KH VWXG\ SRSXODWLRQ FRQVLVWHG RI  PHQ WUHDWHG
ZLWKUDGLFDOSURVWDWHFWRP\53Q RU(%57Q EHWZHHQDQG
2004 without neo- or adjuvant hormonal therapy. The diagnosis of bladder, lung 
and colorectal cancer were established with the ICD-9 and surgery codes, that 
GHᚏQHGH[WLUSDWLYH LQWHUYHQWLRQVDLPHGDWHUDGLFDWLQJWKHVHWKUHHPDOLJQDQFLHV
(cystectomy, lobectomy or pneumectomy and colectomy with or without rectal 
resection). Univariable and multivariable Cox regression analyses addressed the 
rate of secondary malignancies (bladder, lung and rectal cancer).
Results: Overall, 92 (0.9%) cystectomies, 82 (0.8%) lung cancer surgeries 
and 228 (2.2%) surgeries for colorectal cancers were performed. In univariable 
analyses, the rate of cystectomies (log-rank p=0.002), of treatments for lung 
cancer (log-rank p<0.001) and for colorectal cancers (log-rank p<0.001) were 
higher in patients treated with EBRT relative to patients treated with RP. At 
multivariable analyses, after adjusting for age, baseline comorbidities and year 
RIWUHDWPHQWFRGHGLQTXDUWLOHV(%57SUHGLVSRVHGWRDIROGKLJKHUUDWHRI
cystectomy for bladder cancer (p=0.04), to a 1.8-fold higher rate of lung cancer 
resections (p=0.02) and to a 1.7-fold higher rate of rectal cancer (p=0.02).
Conclusions: The increased rate of secondary malignancies after EBRT should 
be considered in localized prostate cancer treatment decision-making.
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PHASE II STUDY OF HYPOFRACTIONATED RADIOTHERAPY
(HYPORT) IN LOCALISED PROSTATE CANCER: REPORT ON ACUTE
AND 18 MONTH LATE TOXICITY
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Introduction & Objectives: Radiobiological studies and preliminary results HYPORT 
trials seems to show that dose per fraction over 2 Gy is safe and can increase the 
therapeutic ratio. Before 10/2004 dose to prostate Planning Target Volume (PTV) in 
curative radiotherapy was 80-82 Gy in 2 Gy-fraction in 8.2 weeks at our institution. 
Our objective to implement HYPORT was to decrease late toxicity while maintaining 
same biochemical control (to keep same equivalent dose). Total treatment time 
UHGXFWLRQFRXOGEHPRUHFRQYHQLHQWWRSDWLHQWVDQG1DWLRQDO+HDOWK6\VWHP
Material & Methods: The study includes 98 consecutive patients with localised 
prostate cancer (PCa). Exclusion criteria: pelvis node irradiation (N1 probability >15% 
DFFRUGLQJ5RDFKIRUPXOD7HFKQLTXHᚏHOGV'&RQIRUPDO570LQLPXPGRVHWR
379SUHVFULEHGGRVH6HWXSFRQWUROZDVRᚎOLQHGD\VZHHNO\DIWHUZDUGV
Dose per fraction 2.6 Gy. Dose to PTV: 67.6-70.2 Gy in 5.2-5.4 weeks. This dose are 
(TXLYDOHQWWR*\LQFRQYHQWLRQDOIUDFWLRQDWLRQ3&D˞˟*\
Results: Minimum follow-up 18 months. Low risk group=56.1%, intermediate=29.6%, 
KLJK ([LWXV ndQHRSODVLD P\RFDUGLDOLQIDUFWLRQ %LRFKHPLFDOFRQWURO
3DWLHQWV ZLWKRXW +7  1DGLU sQJGO DW s
months. Toxicity: Prospective analysis were scored using the RTOG criteria. Acute 
WR[LFLW\ 8URORJLFDO JUDGH       5HFWDO  
    PRQWK /DWH WR[LFLW\ 8URORJLFDO JUDGH    
  5HFWDO    
Conclusions: Hypofractionated accurate radiotherapy in localized prostate cancer 
LVIHDVLEOHZLWKPLQLPDOVLJQLᚏFDQWDFXWHRUODWHWR[LFLW\,QRXUVWXG\$FXWHDQG
months late Toxicity is similar or lower than published high dose normofractionated 
UDGLRWKHUDS\VWXGLHV1RJUDGHVLGHHᚎHFWVZHUHREVHUYHG
